FB 301

Drug Profile

FB 301

Alternative Names: FB-301

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Academia Sinica
  • Developer Cytovance Biologics; Fountain BioPharma
  • Class Antiallergics; Monoclonal antibodies
  • Mechanism of Action IgE receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypersensitivity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergy in USA (Parenteral)
  • 31 Oct 2012 Clinical trials in Hypersensitivity in USA (Parenteral)
  • 06 Apr 2011 Investigation in Hypersensitivity in Taiwan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top